Hormonal Approach for Postmenopausal Vulvovaginal Atrophy.
DHEA
estrogen
hormone therapy
menopause
oxytocin
testosterone
vulvovaginal atrophy
Journal
Frontiers in reproductive health
ISSN: 2673-3153
Titre abrégé: Front Reprod Health
Pays: Switzerland
ID NLM: 9918230899006676
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
09
2021
accepted:
29
10
2021
entrez:
28
10
2022
pubmed:
29
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Menopause is a physiological and progressive phenomenon secondary to decreased ovarian follicular reserve that significantly affects the genital tract. Although postmenopausal vulvovaginal atrophy primarily affects postmenopausal women, it is also seen in premenopausal women. The hypoestrogenic condition results in hormonal and anatomical changes, with the main symptoms, are dryness, burning and genital irritation, decreased lubrication, urinary urgency, dysuria, and recurrent urinary tract infections. This review aims to update hormone therapy for urogenital atrophy, both local and systemic, and discusses the importance of understanding and the need for active treatment of this condition. The main therapeutic objective is the relief of symptoms, and hormonal therapy (HT) is still the most effective choice for treating clinical manifestations, despite the side effects of its use. HT should be used in an individualized way to the needs of the women and appropriate to the stage in which she is menopausal, perimenopausal, or after menopause.
Identifiants
pubmed: 36303971
doi: 10.3389/frph.2021.783247
pmc: PMC9580661
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
783247Informations de copyright
Copyright © 2021 Costa, Sarmento, Vieira-Baptista, Eleutério, Cobucci and Gonçalves.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Hum Reprod Update. 2021 Oct 18;27(6):1115-1150
pubmed: 34432008
Support Care Cancer. 2018 Feb;26(2):643-650
pubmed: 28921241
J Sex Med. 2009 Feb;6(2):334-51
pubmed: 19138368
Cureus. 2021 Aug 26;13(8):e17472
pubmed: 34513524
Menopause. 2006 Nov-Dec;13(6):917-25
pubmed: 17006377
Menopause. 2013 Sep;20(9):888-902; quiz 903-4
pubmed: 23985562
Menopause. 2020 May;27(5):526-534
pubmed: 32049923
Menopause Int. 2011 Dec;17(4):120-5
pubmed: 22120944
Menopause. 2018 Jun;25(6):641-647
pubmed: 29462095
Int J Mol Sci. 2021 Aug 09;22(16):
pubmed: 34445256
Post Reprod Health. 2020 Mar;26(1):32-42
pubmed: 31387514
Menopause. 2017 Jul;24(7):728-753
pubmed: 28650869
J Sex Med. 2006 May;3(3):541-9
pubmed: 16681480
Clin Obstet Gynecol. 2018 Sep;61(3):508-516
pubmed: 29787390
Gynecol Endocrinol. 2021 Aug;37(8):746-752
pubmed: 34169794
Climacteric. 2018 Aug;21(4):326-332
pubmed: 29852797
J Sex Med. 2013 Sep;10(9):2232-41
pubmed: 23809691
Am J Obstet Gynecol. 2016 Dec;215(6):704-711
pubmed: 27472999
Endocrinol Metab Clin North Am. 2015 Sep;44(3):497-515
pubmed: 26316239
Eur J Obstet Gynecol Reprod Biol. 2018 Oct;229:45-56
pubmed: 30103082
Fertil Steril. 2002 Apr;77 Suppl 4:S83-8
pubmed: 12007909
Curr Womens Health Rep. 2002 Aug;2(4):305-11
pubmed: 12150759
J Low Genit Tract Dis. 2011 Oct;15(4):263-7
pubmed: 21959570
Horm Mol Biol Clin Investig. 2017 Feb 1;29(2):39-60
pubmed: 27997350
Menopause. 2019 Apr;26(4):431-453
pubmed: 30363010
Mayo Clin Proc. 2017 Dec;92(12):1842-1849
pubmed: 29202940
Clin Breast Cancer. 2019 Dec;19(6):e731-e740
pubmed: 31522958
Gynecol Endocrinol. 2012 Oct;28 Suppl 2:7-11
pubmed: 22849758
Menopause. 2014 Oct;21(10):1063-8
pubmed: 25160739
Post Reprod Health. 2015 Sep;21(3):88-97
pubmed: 25995333
Gynecol Endocrinol. 2021 Aug;37(8):740-745
pubmed: 34036849
Menopause. 2018 Jul;25(7):837-847
pubmed: 29870471
J Menopausal Med. 2015 Aug;21(2):65-71
pubmed: 26357643
Menopause. 2012 Aug;19(8):886-93
pubmed: 22453200